Wadud Z, Chintakayala P. Personal carbon trading: trade-off and complementarity between in-home and transport related emissions reduction. Ecol Econ. 2019 Feb;156:397-408. doi: 10.1016/j.ecolecon.2018.10.016
Ko DT, Khan AM, Kotrri G, Austin PC, Wijeysundera HC, Koh M, Chu A, Jackevicius CA, Lawler PR, Tu JV. Eligibility, clinical outcomes, and budget impact of PCSK9 inhibitor adoption: the CANHEART PCSK9 study. J Am Heart Assoc. 2018 Nov 6;7(21):e010007. doi: 10.1161/JAHA.118.010007
Lairson DR, Parikh RC, Cormier JN, Wenyaw C, Du XL. Cost-utility analysis of treatments for advanced non-small cell lung cancer. Am J Pharm Benefits. 2015 Nov;7(6):271-9.
Van Houtven G, Mansfield C, Phaneuf DJ, von Haefen R, Milstead B, Kenney MA, Reckhow KH. Combining expert elicitation and stated-preference methods to value ecosystem services from improved lake water quality. Ecol Econ. 2014 Mar;99:40-52. doi: 10.1016/j.ecolecon.2013.12.018.
Patorno E, Glynn RJ, Hernandez-Diaz S, Avorn J, Wahl PM, Bohn RL, Mines D, Liu J, Schneeweiss S. Risk of ischemic cerebrovascular and coronary events in adult users of anticonvulsant medications in routine care settings. J Am Heart Assoc. 2013 Jul 30;2(4):e000208. doi: 10.1161/JAHA.113.000208.
Lopes M, Chulikavit M, Parikh R, Stern L, Liu Z, Rogerio J. Budget impact of everolimus in treating metastatic renal cell carcinoma. Am J Pharm Benefits. 2012;4(Special Issue):sp41-8.
Bristow AL, Wardman M, Zanni AM, Chintakayala PK. Public acceptability of personal carbon trading and carbon tax. Ecol Econ. 2010 Jul 15;69(9):1824-37. doi: 10.1016/j.ecolecon.2010.04.021